Everolimus for preventing organ rejection
Everolimus has been licensed for the prevention of organ rejection after kidney, heart or liver transplant. For this indication, the medicine is available in 0.25mg, 0.5mg and 0.75mg tablets called Certican (Novartis). For kidney and heart transplant, Certican tablets should be used in combination with ciclosporin for microemulsion and corticosteroids. For liver transplant, it should be used in combination with tacrolimus and corticosteroids.
Citation: The Salvadore DOI: 10.1211/PJ.2015.20068496
Recommended from Pharmaceutical Press
A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.£38.00